[ad_1]
Investment Research Report
[Informe de investigación incondicional]With the accelerating popularity of new energy vehicles, the value of this track has tripled! The leading market share has surpassed 30% and it just won big orders from Tesla and SAIC.
[Informe de investigación incondicional]The Chief Military Engineer Prelude Has Been Opened! The CICC shouted that the main line of investment has been found. Is this giant with the largest scale of assets in the country and the sixth largest income in the world is its main asset?
[Hardcore Research Report]Agricultural chips are “independent and controllable”, and the genetically modified seed industry will be catalyzed again by politics, and the growth leader will enjoy a valuation premium!
[ETF Investment Daily]Agriculture, forestry, livestock and fisheries have exploded Agriculture ETF PK Pig ETF, which one to buy?
Original title: Six new varieties of corona vaccines have begun phase III clinical trials and the performance of vaccine stocks has exploded. How to implement?
Source: China Business News
In the recently released 2020 performance forecast, most vaccine stocks expect their 2020 performance to increase significantly.
On February 19, the State Food and Drug Administration released the latest advances in research and development of the new coronavirus vaccine, saying it is actively promoting research and development and commercialization of the new vaccine against the coronavirus. Currently, it has conditionally approved the list of 2 new coronavirus vaccines in my country, and urgently approve 5 technical routes for 16 varieties of vaccines. Carrying out clinical trials, of which 6 varieties of vaccines have started phase III clinical trials.
Previously, on February 5, the National Medical Products Administration had conditionally approved the application for registration of Beijing Kexing Zhongwei Biotechnology Co., Ltd.’s new coronavirus inactivated vaccine (Vero cell) This vaccine is the second new corona approved for its commercialization in China. Vaccine, in Turkey phase III, data show that the vaccine protection rate reached 91.25%.
In the A-share market, buoyed by good news, vaccine stocks ushered in a wave of rebound around the Spring Festival. At the close of today,Color ladderThe biological vaccines sector rose 1.63%, within the sectorJunzheng Group、Biological TiankangDaily limit,Unnamed medicineIt was up more than 9% and Wanfang Bio-tech was up almost 7%.
In the recently released 2020 performance forecast, more than 30 publicly traded bio-vaccine companies have disclosed their performance forecasts and 20 vaccine stocks are expected to increase their performance in 2020.
among themDaan Gene、Oriental Bio、BGIThree stocks are among the top three, with the highest net earnings growth in 2020 forecast to be 2,287%, 1,795% and 732%.
Galaxy Securities believes it will continue to benefit the in vitro testing and vaccine industries around the Spring Festival. Large-scale population movements and high-frequency nucleic acid testing will bring in tens of billions or even hundreds of billions of market demand. The vaccine segment has entered a profitable design stage. Considering that only vaccination can achieve true universal immunity, and the mutation of the virus promotes the derivation of vaccines into a new series of multivalent vaccines, the vaccine segment is expected to benefit in the future. -It was epidemic for a long time.
Everbright ValuesIt is noted that companies in the vaccine industry chain are expected to benefit directly from the progress of research, development and vaccination of new corona vaccines. The new corona epidemic has taken the importance of vaccine research, development and industrialization to an unprecedented level. pay attentionKanghua Bio、Zhifei、Kangtai Bio、Hualan Bio、Wantai Bio、Watson Bio、Fosun Pharma、CansinoBiology, etc.
Sina Statement: This news is a reprint of Sina Cooperative Media. Posting this article on Sina.com for the purpose of conveying more information does not mean that I agree with their views or confirm their description. The content of the article is for reference only and does not constitute investment advice. Investors trade accordingly at their own risk.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in Charge: Zhang Shuyuan
